FOR IMMEDIATE RELEASE

Emotional Biomarkers Emerge as the Missing Variable in Biotechnology, Longevity, and Clinical Trial Design, According to Industry Experts

ZÜRICH, Switzerland — A growing body of peer-reviewed research is pointing to a measurement gap that has quietly influenced clinical trial outcomes, longevity research, and nutraceutical development for decades: the absence of objective, continuous data on a patient's emotional-physiological state.

For more than 70 years, biotechnology and clinical medicine have advanced primarily through the measurement of molecular and genetic data — DNA sequencing, proteomics, and epigenetics among them. Industry experts now suggest that emotional homeostasis, long treated as a variable external to biology, may represent the next major measurement frontier.

"Every major breakthrough in biotechnology came from making an invisible biological process visible," said Tatiana Denisenco, a Board Advisor and Global Growth Executive with over 20 years of experience across biotechnology, longevity science, and international brand strategy. "Emotional homeostasis is the next one. For decades the industry treated emotional state as noise outside the biology. It isn't. It is the biology."

Research in psychoneuroimmunology has established that chronic psychological stress activates the hypothalamic-pituitary-adrenal axis, elevating cortisol and influencing immune function, inflammation, and recovery. Separately, research published in the Proceedings of the National Academy of Sciences has linked elevated perceived stress to measurably shorter telomeres — a recognized marker of accelerated biological aging.

The clinical trial implications are significant. Published research in The Lancet describes placebo and nocebo effects as complex neurobehavioral phenomena driven by patient expectation and emotional context — phenomena that can reach response rates of 40 to 50 percent in psychiatric and longevity-focused trials. Industry analysts note that an inability to separate these emotionally driven responses from a treatment's true biochemical effect has contributed to high failure rates in Phase II and Phase III clinical trials, particularly in neurology, psychiatry, and longevity medicine.

"When a therapy produces inconsistent results across patients with similar biological profiles, researchers traditionally look to genetics or metabolism for an explanation," Denisenco said. "Increasingly, the missing variable may be the emotional-physiological state of the patient — a factor that has never been measured continuously or objectively in most clinical trial designs."

A wave of deep-tech companies, primarily in Europe, is now developing wearable and AI-based platforms designed to convert physiological signals — including heart rate variability, electrodermal activity, and skin temperature — into continuous, objective emotional-state data. Switzerland has emerged as a notable hub for this category of innovation, with several Swiss deep-tech ventures gaining recognition from national innovation agencies and international technology showcases.

Industry observers say the implications extend across three sectors:

In biotechnology, objective emotional biomarkers could help explain treatment variability between patients, improve stratification in clinical trials, and contribute to more complete biological datasets that account for the physiological conditions under which cellular processes occur.

In longevity science, where cellular senescence, inflammation, and mitochondrial health are influenced by chronic stress, researchers say measuring the emotional environment may become as important as measuring biological age itself.

In the nutraceutical sector, where efficacy claims for stress reduction, sleep support, and cognitive performance have historically relied on self-reported outcomes, objective emotional-state data could provide a new category of evidence as regulators and investors increasingly demand measurable validation over marketing claims.

"This is not a replacement for existing clinical endpoints," Denisenco said. "It is an additional layer of intelligence that helps explain why outcomes differ between patients who appear identical on paper. The future of precision medicine may not be limited to understanding what happens inside a cell. It may require understanding the emotional state in which that cell is operating."

Industry experts anticipate that regulatory bodies, including the U.S. Food and Drug Administration and the European Medicines Agency, will face increasing pressure to incorporate continuous patient experience data into clinical trial frameworks for central nervous system and longevity-focused therapeutics over the coming decade.

About Tatiana Denisenco

Tatiana Denisenco is a Board Advisor and Global Growth Executive with over 20 years of leadership experience across biotechnology, longevity science, FMCG, and international brand strategy. She has directed peer-reviewed clinical studies in the biotechnology sector, led the strategic turnaround and , and contributed to the development of longevity-focused healthcare concepts in Switzerland. She is based in Zürich, Switzerland.

Media Contact:
Tatiana Denisenco
[email protected]
+41 78 732 79 48
Zürich, Switzerland